Lantheus Medical Imaging will supply its experimental F-18-labeled PET imaging radiotracer MK-6240 for a large U.S. trial to investigate differences in brain pathology in people with varying types of dementia.
The National Institute on Aging-led study is named the Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) trial and will involve all 37 Alzheimer’s disease research centers in the U.S. The five-year trial will recruit 2,000 subjects and collect their imaging and blood-based biomarker data to generate etiologic profiles for cases of mixed dementia, the company said.
F-18 MK-6240 radiotracer targets aggregated tau protein to visualize neurofibrillary tangles, a hallmark of several neurodegenerative diseases, including Alzheimer’s disease, according to the firm.
Sterling Johnson, PhD, a professor of medicine at the University of Wisconsin, is the CLARiTI study lead. More information about the trial can be found here, Lantheus added.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
